| Name | Title | Contact Details |
|---|
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 48,000 employees around the world, the company contributes to sustainable society by providing solutions to the worlds challenges through its three business sectors of Material, Homes, and Health Care.
We are a trusted leader in providing integrated solutions, leveraging cutting-edge technology to deliver exceptional customer experiences. With a dedicated team and a commitment to excellence, we are redefining industry standards and creating a brighter future for our clients and their customers. Our mission is to make lives better. We engage, listen, and resolve consumer concerns and obligations with empathy and innovation. We advocate for our clients brands and reputations as our own. Follow us, and discover the power of InteLogix.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
The Federal Community Defender Office for the Eastern District of Pennsylvania, an office within the Defender Association of Philadelphia, is the designated Federal Community Defender Organization for the United States District Court for the Eastern District of Pennsylvania. Since its creation in 1972, the Federal Community Defender Office has been funded to render Defender Services to individuals who are unable to afford counsel and who are under investigation for, or charged with, violations of the laws of the United States, and to federal death-sentenced prisoners in Pennsylvania and elsewhere, when appointed. Upon appointment by the District Court or the Third Circuit Court of Appeals, the office provides representation for individuals who have been subpoenaed to appear before investigating Grand Juries, who are named defendants in criminal complaints, or who have been indicted by a Grand Jury. The representation, once undertaken, remains throughout the pendency of the proceedings, up to and including applications for relief to the Supreme Court of the United States. In addition, upon appointment, the office represents state and federal prisoners who are seeking relief by way of Habeas Corpus application in both the District Court and the Court of Appeals.
Whether youre on the road or on the water, we supply premium RV, automotive, and marine products designed to enhance your fun. Our team is committed to always thinking about your next journey — pushing the possibilities of our products and services, all to better your time spent outdoors, whenever, wherever, for years to come.